JP7179733B2 - Ｍｃｌ－１阻害剤及びタキサン化合物の組み合わせ物、その使用及び医薬組成物 - Google Patents

Ｍｃｌ－１阻害剤及びタキサン化合物の組み合わせ物、その使用及び医薬組成物 Download PDF

Info

Publication number
JP7179733B2
JP7179733B2 JP2019536593A JP2019536593A JP7179733B2 JP 7179733 B2 JP7179733 B2 JP 7179733B2 JP 2019536593 A JP2019536593 A JP 2019536593A JP 2019536593 A JP2019536593 A JP 2019536593A JP 7179733 B2 JP7179733 B2 JP 7179733B2
Authority
JP
Japan
Prior art keywords
phenyl
pyrimidin
thieno
oxy
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019536593A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020503361A (ja
Inventor
ポーター，デール
ハリロヴィッチ，エンサー
シャンリオン，マイア
マラグノ，アナ・レティシア
ジェネステ，オリヴィエ
メリノ，デルフィーヌ
ホイットル，ジェームズ
ヴァイヤン，フランソワーズ
ビジヴァーダー，ジェーン
リンデマン，ジェフリー
レッセン，ギヨーム
マランゴーニ，エリザベッタ
Original Assignee
レ ラボラトワール セルヴィエ
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レ ラボラトワール セルヴィエ, ノバルティス アーゲー filed Critical レ ラボラトワール セルヴィエ
Priority claimed from PCT/EP2018/050298 external-priority patent/WO2018127575A1/en
Publication of JP2020503361A publication Critical patent/JP2020503361A/ja
Application granted granted Critical
Publication of JP7179733B2 publication Critical patent/JP7179733B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2019536593A 2017-01-06 2018-01-05 Ｍｃｌ－１阻害剤及びタキサン化合物の組み合わせ物、その使用及び医薬組成物 Active JP7179733B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762443082P 2017-01-06 2017-01-06
US62/443,082 2017-01-06
EP17157779.4 2017-02-24
EP17157779 2017-02-24
US201762527360P 2017-06-30 2017-06-30
US62/527,360 2017-06-30
PCT/EP2018/050298 WO2018127575A1 (en) 2017-01-06 2018-01-05 Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
JP2020503361A JP2020503361A (ja) 2020-01-30
JP7179733B2 true JP7179733B2 (ja) 2022-11-29

Family

ID=61007674

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019536593A Active JP7179733B2 (ja) 2017-01-06 2018-01-05 Ｍｃｌ－１阻害剤及びタキサン化合物の組み合わせ物、その使用及び医薬組成物

Country Status (20)

Country Link
US (1) US10765680B2 (ko)
EP (1) EP3565547B1 (ko)
JP (1) JP7179733B2 (ko)
KR (1) KR102576567B1 (ko)
CN (1) CN110381937A (ko)
AU (1) AU2018205735B2 (ko)
BR (1) BR112019013907A2 (ko)
CA (1) CA3049095C (ko)
CL (1) CL2019001859A1 (ko)
CO (1) CO2019007261A2 (ko)
CU (1) CU20190064A7 (ko)
GE (1) GEP20227372B (ko)
IL (1) IL267791B (ko)
JO (1) JOP20190159B1 (ko)
MA (1) MA47198A (ko)
MX (1) MX2019008109A (ko)
PH (1) PH12019501451A1 (ko)
RU (1) RU2763544C2 (ko)
UA (1) UA125142C2 (ko)
ZA (1) ZA201904280B (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020254299A1 (en) * 2019-06-17 2020-12-24 Les Laboratoires Servier Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015129120A (ja) 2013-12-23 2015-07-16 レ ラボラトワール セルヴィエ 新規なチエノピリミジン誘導体、その製造方法及びそれを含有する医薬組成物
US20150352097A1 (en) 2011-03-08 2015-12-10 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
WO2016207217A1 (en) 2015-06-23 2016-12-29 Les Laboratoires Servier New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100870314B1 (ko) * 2008-02-19 2008-11-25 고려대학교 산학협력단 암 치료용 핵산 의약 조성물
CN105311016A (zh) 2014-07-24 2016-02-10 中国科学院大连化学物理研究所 一种抗细胞凋亡Mcl-1蛋白抑制剂及其应用
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) * 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN209805646U (zh) * 2017-08-02 2019-12-17 株式会社村田制作所 致动器

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150352097A1 (en) 2011-03-08 2015-12-10 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
JP2015129120A (ja) 2013-12-23 2015-07-16 レ ラボラトワール セルヴィエ 新規なチエノピリミジン誘導体、その製造方法及びそれを含有する医薬組成物
WO2016207217A1 (en) 2015-06-23 2016-12-29 Les Laboratoires Servier New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Basic Science，2016年，Vol.27,Suppl.9,ix4，12P
European Journal of Pharmaceutical Sciences，NL，2015年，Vol. 70，pp. 64 - 71，http://dx.doi.org/10.1016/j.ejps.2015.01.003
International Journal of Oncology，2016年，49，pp.402-410
Oncol.Res.Treat.，2016年，39(suppl 3)，p.117 V387

Also Published As

Publication number Publication date
KR102576567B9 (ko) 2023-12-15
CU20190064A7 (es) 2020-02-04
JP2020503361A (ja) 2020-01-30
ZA201904280B (en) 2022-03-30
MA47198A (fr) 2019-11-13
EP3565547B1 (en) 2024-03-13
MX2019008109A (es) 2019-09-04
RU2019123982A (ru) 2021-02-08
CA3049095C (en) 2022-01-25
CA3049095A1 (en) 2018-07-12
CN110381937A (zh) 2019-10-25
EP3565547A1 (en) 2019-11-13
RU2019123982A3 (ko) 2021-03-25
BR112019013907A2 (pt) 2020-02-04
AU2018205735B2 (en) 2024-02-01
AU2018205735A1 (en) 2019-07-11
JOP20190159A1 (ar) 2019-06-25
KR20190103317A (ko) 2019-09-04
UA125142C2 (uk) 2022-01-19
GEP20227372B (en) 2022-04-25
IL267791A (en) 2019-09-26
PH12019501451A1 (en) 2020-06-01
CO2019007261A2 (es) 2019-07-31
KR102576567B1 (ko) 2023-09-07
JOP20190159B1 (ar) 2023-09-17
IL267791B (en) 2022-02-01
US20190336505A1 (en) 2019-11-07
RU2763544C2 (ru) 2021-12-30
US10765680B2 (en) 2020-09-08
CL2019001859A1 (es) 2019-11-15

Similar Documents

Publication Publication Date Title
TWI674898B (zh) Mcl-1抑制劑及紫杉烷化合物之組合，及其用途及醫藥組合物
PT2127652E (pt) Agente libertador da hormona estimuladora dos folículos
KR20130140071A (ko) 항종양 알칼로이드를 이용한 병용요법
KR20140073521A (ko) N-히드록시-4-｛2-[3-(n,n-디메틸아미노메틸)벤조퓨란-2-일카르보닐아미노]에톡시｝벤즈아마이드의 투여 방식
TWI557128B (zh) 組成物在製備用於預防或治療非小細胞肺癌之藥物之用途
JP7179733B2 (ja) Ｍｃｌ－１阻害剤及びタキサン化合物の組み合わせ物、その使用及び医薬組成物
CN111032050B (zh) Mcl-1抑制剂与用于血液癌症的标准治疗的组合，其用途和药物组合物
WO2020254299A1 (en) Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof
WO2020099542A1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
US20150110864A1 (en) Novel antitumor agent comprising combination of three agents
EA040162B1 (ru) Комбинация mcl-1 ингибитора и таксанового соединения, их применения и фармацевтические композиции
US20170340629A1 (en) Masitinib combination for use in treating breast cancer
TW201800091A (zh) 包含奎寧鹽懸浮液的用於抗癌治療的局部給藥用注射劑組合物
KR20230140557A (ko) 암 치료를 위한 나트륨 트랜스-[테트라클로리도비스(1h-인다졸)루테네이트(iii)]의 용도
EA044971B1 (ru) Комбинация ингибитора mcl-1 и мидостаурина, ее применения и фармацевтические композиции
OA19591A (en) Combination of a Mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof.
JP2005507410A (ja) Ｂｃｒ／ａｂｌキナーゼ活性のＡＴＰ競合的阻害剤とチロホスチンアナログとの組合せ剤
JP2015163591A (ja) 抗癌剤の併用による癌治療方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201203

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220929

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221018

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221116

R150 Certificate of patent or registration of utility model

Ref document number: 7179733

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150